Analysis of renal function during angiostatic therapy with the COX-II inhibitor rofecoxib, in combination with pioglitazone, and trofosfamide or capecitabine in patients with metastatic / advanced cancer.

Abteilung für Hämatologie und Internistische OnkologieKlinikum der Universität Regensburg0 sites87 target enrollmentJune 22, 2009

Overview

Phase: Phase 2
Intervention: Not specified
Conditions: C80
Sponsor: Abteilung für Hämatologie und Internistische OnkologieKlinikum der Universität Regensburg
Enrollment: 87
Status: Completed
Last Updated: last year

No summary available.

Registry

who.int

Start Date

June 22, 2009

End Date

October 4, 2005

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Abteilung für Hämatologie und Internistische OnkologieKlinikum der Universität Regensburg

•Patients with either gastrointestinal cancer, including pancreatic, and gall bladder cancer or urological cancer (group A) or metastatic melanoma, sarcoma, pulmonary and gynecological carcinoma or hematological malignancy (group B) were included in the. Additional eligibility criteria included: adequate baseline organ function as evidenced by a serum creatinine concentration at or below 1\.8mg/dl, GOT, GPT and GGT below 1\.25 times the normal concentration, white blood cell count over 2\.0 cells per nL and a platelet count over 100000 cells per µL. Written informed consent had to be obtained before inclusion in the study.

•Patients with significant comorbidity including acute infections, inadequately controlled diabetes mellitus, congestive heart failure, angina pectoris and cardiac arrhythmia requiring medical therapy were excluded from the study.